-

09:47:29 AM

ZLAB Stock News

ZLAB - Zai Lab Limited

08/09/22 4:05 PM

Nasdaq : ZLAB

earnings

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by ZEJULA; strong balance sheet with a cash position of $1.26 billion Company to host a conference call and

RHEA-AI

positive

07/19/22 7:38 AM

Nasdaq : ZLAB

earnings

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today

RHEA-AI

neutral

07/17/22 8:00 PM

Nasdaq : ZLAB

Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs

Inclusion of Zai Lab shares in Shanghai-Hong Kong Stock Connect is effective today Zai Lab has been dual-primary listed on Nasdaq and the Hong Kong Stock Exchange, and its shares included in the Shenzhen-Hong Kong Stock Connect since June 2022 Zai Lab’s inclusion in two Stock Connect Programs

RHEA-AI

very positive

07/13/22 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global

RHEA-AI

positive

06/27/22 12:00 AM

Nasdaq : ZLAB

Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

Zai Lab Limited

RHEA-AI

neutral

06/10/22 7:30 AM

Nasdaq : ZLAB

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Potential best-in-class therapy for ROS1-positive metastatic NSCLC and

RHEA-AI

very positive

06/03/22 8:00 AM

Nasdaq : NVCR, ZLAB

clinical trial

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Novocure, a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab, an...

RHEA-AI

neutral

06/03/22 8:00 AM

Nasdaq : ZLAB

clinical trial

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

RHEA-AI

neutral

05/31/22 8:00 AM

Nasdaq : ZLAB

conferences

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

Presentation features a new subgroup analysis of the Phase 3 PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their response to first-line platinum-based chemotherapy Results showed a significant extension of

RHEA-AI

neutral

05/24/22 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations at June Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

ZLAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zailaboratory.com
Security nameZai Lab Limited - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressPudong
StateShanghai
CityShanghai
Zip201210
CountryChina (Mainland)

About Zai Lab Limited

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.